Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667439 | 0.92 | — | — | |
| SCHEMBL8408343 | 0.80 | — | — | |
| SCHEMBL4332885 | 0.77 | — | — | |
| SCHEMBL3955091 | 0.71 | — | — | |
| SCHEMBL20055717 | 0.71 | HSD17B10 (0.42) | HSD17B10 | |
| SCHEMBL18507037 | 0.71 | HSD17B10 (0.48) | TRIM24TRIM33HSD17B10KMT2A | |
| SCHEMBL7598 | 0.71 | — | — | |
| SCHEMBL3950444 | 0.71 | — | — | |
| SCHEMBL8729 | 0.71 | — | — | |
| SCHEMBL13356210 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013021051-A1 | ANTIBACTERIAL HOMOPIPERIDINYL SUBSTITUTED 3,4 DIHYDRO 1H [1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
| US-8137687-B2 | Implantable medical device having a coating of a biocompatible polylactone from N-substituted 4-aza-caprolactone | MEDTRONIC VASCULAR, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8137687-B2 | Implantable medical device having a coating of a biocompatible polylactone from N-substituted 4-aza-caprolactone | MEDTRONIC VASCULAR, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080233169-A1 | 4-Aza-Caprolactone-Based Polymeric Compositions Useful for the Manufacture of Biodegradable Medical Devices and as Medical Device Coatings | MEDTRONIC VASULAR, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080233169-A1 | 4-Aza-Caprolactone-Based Polymeric Compositions Useful for the Manufacture of Biodegradable Medical Devices and as Medical Device Coatings | MEDTRONIC VASULAR, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233169-A1 | 4-Aza-Caprolactone-Based Polymeric Compositions Useful for the Manufacture of Biodegradable Medical Devices and as Medical Device Coatings | CAD, ACMSD, TET3 | TRIM24 994/4885TRIM33 1169/4885ALDH1A1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.